P1‐056: Idalopirdine, A 5‐HT6 Antagonist in Phase III Development as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild‐to‐Moderate Alzheimer’s Disease: Baseline Data from the Ongoing Starshine Study

III DEVELOPMENTAS ADJUNCTIVE THERAPY TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE: BASELINE DATA FROM THE ONGOING STARSHINE STUDY Alireza Atri, Neli Boneva, Jeffrey L. Cummings, Lutz Fr€olich, Pierre N. Tariot, Kristian Windfeld, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco, CA, USA; 3 H. Lundbeck A/S, Copenhagen, Denmark; 4 Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 5 Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany; Banner Alzheimer’s Institute, Phoenix, AZ, USA. Contact e-mail: cumminj@ccf.org